Rambam health care campus, Haifa, Israel

Slides:



Advertisements
Similar presentations
Agents Used in the Treatment of Hyperlipidemia
Advertisements

Monascus rice powder co-supplemented with coenzyme Q 10 improves serum lipids and LDL-lag time on hypercholesterolemia subjects. Shih-Wen Hsu 1#, Yi-Ting.
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
More Facts on Fats Lipids and Health.
Free radicals and antioxidants in health and disease
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
Global impact of ischemic heart disease World Heart Federation, 2011.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
Kirk Mykytyn, Ph.D. Department of Pharmacology
Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.
Cholesterol is among the lipids (fats) in the bloodstream. Source: Supplied from diet or synthesized by liver. Importance: 1.Form cell membranes and.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Copyright® Raisio A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol.
Case 15 Andrea De Mesa. Patient history A 44 y/o male, single, undergoes cardiovascular screening on advice of his attending physician. He is a smoker.
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Hyperlipidemia Hyperlipidemia and hyperlipoproteinemia are general terms for elevated concentrations of lipids and lipoproteins in the blood. hypercholesterolemia.
Chapter 21 Agents Used in the Treatment of Hyperlipidemia.
LAB (6): LIPIDS PROFILE KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2013.
HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.
Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral artery disease Annunziata Lapolla; Francesco.
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans Bonnie Ky, MD,* Anne Burke, MD,* Sotirios Tsimikas,
EFFECT OF COFFEA ARABICA ON STREPTOZOTOCIN- INDUCED DIABETES MELLITUS IN WISTAR RATS Ndife NG 1, Olayaki LA 1, Okesina KB 1*, Alagbonsi IA 1,2 1 Department.
Lab (6): Lipids profile KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2012 T.A Nouf Alshareef
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Triglyceride determination
Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic.
Drugs for Lipid Disorders
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
Triglycerides (mmol/L)
Contribution of Oxidized Low Density Lipoprotein and Nitric Oxide in the Pathogenesis of Early Onset Acute Myocardial Infarction in Egyptian population.
Dr. Syed Waleem Pasha Assistant Professor Yenepoya Medical College
Elevated Circulating Levels of Inflammatory Markers in
TOTAL CHOLESTEROL.
Miss.Shuchismita Behera Miss.Sujata Dixit Dr.G.Bulliyya Dr.S.K.Kar
Practical Analysis Using Spectrophotometer
Update on Clinical Trials with Novel CETP Inhibitors to Raise HDL: Where are We Today? H. Bryan Brewer, Jr. Washington Cardiovascular Associates Washington.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Mohamed Elbandy1, 2 and Ihab Ashoush3
ELIGIBILITY: MRC/BHF Heart Protection Study
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
The ASSERT Study.
“Sick Fat,” Metabolic Disease, and Atherosclerosis
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Weight Management the natural way
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
Cardiovascular System
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Case 1: A 73-year-old white female with carotid disease
Type 2 diabetes: Overlap of clinical conditions
Section 7: Aggressive vs moderate approach to lipid lowering
Hyperlipidemia: A well-documented modifiable risk factor for stroke
LRC-CPPT and MRFIT Content Points:
Section IV: The interaction of the RAS and lipids
The Effect of Pomegranate Extract on Survival and Peritoneal Bacterial Load in Cecal Ligation and Perforation Model of Sepsis in Rats Shahryar Eghtesadi,Sanaz.
Baseline Characteristics of the Subjects*
Major classes of drugs to reduce lipids
NGM282 in NASH: 3 mg QD (phase 2)
The Health Benefits of Isotonix OPC-3®
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Lipoproteins   Macromolecular complexes in the blood that transport lipids Apolipoproteins   Proteins on the surface of lipoproteins; they play critical.
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Section 6: Update on lipid treatment guidelines
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Rambam health care campus, Haifa, Israel Niacin Administration significantly reduced Oxidative Stress in Patients with Hypercholesterolemia and Low HDL  

Rambam health care campus, Haifa, Israel Shadi Hamoud, Marielle Kaplan, Edna Meilin, Ahmad Hassan, Rafael Torgovicky, Raanan Cohen, Tony Hayek   Internal Medicine E department, The Lipid Research Laboratory, The Clinical biochemistry Laboratory. Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, Israel.   Merck, Sharp and Dohme, Medical Department, Israel The American Journal of the Medical Sciences 345(3) · September 2012 

Background Rambam health care campus, Haifa, Israel Oxidative stress has been implicated in the pathogenesis of cardio-vascular disorders, including atherosclerosis. Mechanism: promoting lipid peroxidation of serum lipoproteins, enhancing their pro-atherogenic properties Serum paraoxonase (PON1), an HDL-associated esterase, was shown to protect lipoproteins and atherosclerotic lesions against lipid peroxidation

Background Rambam health care campus, Haifa, Israel Hypercholesterolemia is associated with increased oxidative stress Hypercholesterolemic patients are prone to accelerated atherosclerosis and resulting cardiovascular complications. Moreover, lower levels of blood HDL-c are also associated with higher rate of atherosclerotic cardiovascular complications

Background Rambam health care campus, Haifa, Israel Protection from oxidative stress may be achieved by: Endogenous antioxidants, such as the enzymes superoxide dismutase, catalase and glutathione reductase Exogenous antioxidants, like nutritional antioxidants including tocopherols, ascorbic acid, carotenoids and polyphenols, extracts from red wine, pomegranate juice and licorice root In pharmacological doses niacin (Vitamin B3) was proved to reduce total cholesterol, triglycerides, VLDL and LDL, and to increase HDL levels.

Background: NIACIN Rambam health care campus, Haifa, Israel vitamin B3 or nicotinic acid A water-soluble vitamin. Organic compound derivative of pyridine 2000-6000 mg daily blocks the breakdown of fats in adipose tissue, more specifically the very-low-density lipoprotein (VLDL). Causes a decrease in free fatty acids in the blood and, as a consequence, decreased secretion of VLDL and cholesterol by the liver. By lowering VLDL levels, niacin also increases the level of high-density lipoprotein cholesterol in blood, and therefore it is sometimes prescribed for patients with low HDL-c, who are also at high risk for myocardial infarcts

AIM Rambam health care campus, Haifa, Israel To study the Effects of Niacin Administration for Patients with Hypercholesterolemia and low HDL-cholesterol (HDL-c) on their serum Oxidative Stress as well as inflammatory status.

PATIENTS & METHODS Rambam health care campus, Haifa, Israel Seventeen patients with hypercholesterolemia and low HDL-c (<40 MG%) Eight healthy matching control subjects were enrolled in the study. Patients treated with niacin for twelve weeks. Lipid profile, oxidative stress parameters (TBARS & Lipid peroxides) and CRP levels were determined at the time of enrollment, two weeks and twelve weeks after initiation of niacin treatment.

STATISTICAL METHODS Rambam health care campus, Haifa, Israel Statistical analyses included the use of the Student’s t-test, when comparing the means of two groups. ANOVA was used when more than two groups were compared. Results are given as mean ± SEM.

RESULTS Rambam health care campus, Haifa, Israel Subjects with lower HDL-c exhibited higher oxidative stress compared to subjects with normal HDL-c.

Patient treated group (n=14) Rambam health care campus, Haifa, Israel RESULTS   Patient treated group (n=14) Control group (n=8) p-value Age (years) 48.5 49.5 N.S. Gender (%) Males (9) 64% Females (5) 36% Males (4) 50% Females (4/8) 50% Mean statin dose (equivalent to simvastatin (mg)) 45.8 ______ HDL (mg/dl) 37.3 52.2 0.0012 LDL (mg/dl) 115.1 143.7 0.015 Triglycerides (mg/dl) 202 98 0.039 hs C-Reactive protein (mg/L) 3.734 1.94 0.097 Baseline characteristics of the Patient treated group and the control groups

RESULTS Rambam health care campus, Haifa, Israel Niacin treatment to hypercholesterolemic patients caused a significant increase ( by 10.5%) in HDL-c levels, and in Apolipoprotein A1 levels (by 8%) A decrease by 24% in triglyceride levels. Niacin also significantly reduced oxidative stress, as measured by a significant decrease in serum content of TBARS, lipid peroxides and paraoxonase activity by up to12%, 40% and 12% respectively, compared to levels before treatment. Although CRP serum levels were not affected by Niacin treatment, a correlation between CRP levels and HDL levels was obtained when computing all the results. SAFETY MEASURES: No elevation of liver enzymes was observed One patient exhibited adverse side effects (intractable flushing with pruritus that started after doubling the niacin dose)

+10.1%, p=0.04 +10.4%, p=0.002

-23%, p=0.042 -24.2%, p=0.013 Triglycerides (mg/dl)

-10% P=0.012 -12% P=0.011

-33% P=0.04 -40% P=0.003 Basal PD (nmol/ml)

Correlation between HDL & CRP Levels

CONCLUSION Rambam health care campus, Haifa, Israel Niacin treatment to hypercholesterolemic patients with low HDL levels caused a significant decrease in their oxidative stress status. These results indicate an additional beneficial effect of Niacin beyond its ability to affect lipid profile

DISCUSSION Rambam health care campus, Haifa, Israel Our study demonstrates that administration of niacin to patients with hypercholesterolemia and low HDL-c (<40 mg%) had favorable effects, both on the serum lipid profile, mainly on the HDL-c and triglyceride levels, and on the patients serum oxidative stress. Previous studies have demonstrated that treatment with niacin for 19 weeks caused a 24% increment in the HDL-C levels (by increasing the level of Apolipoprotein A I – ApoAI). It should be noticed that despite being the patients treated with statin medications and having significantly lower values of LDL than the subjects in the control group, the patients' group had significantly higher rates of oxidative stress before treatment . In our study, Niacin treatment significantly reduced the treated patients’ oxidative stress, including paraoxonase activity. There are no published studies examining the direct effect of niacin to hypercholesterolemic patients on their oxidative stress. Ganji et al (26) showed in vitro that niacin inhibits vascular inflammation by decreasing LDL-c oxidation and inflammatory cytokines production using cultured human aortic endothelial cells.

DISCUSSION Niacin, by increasing the level of HDL-c in blood, induces HDL activities, resulting in the anti-atherogenic activity through the observed favorable effect on the lipid profile on the one hand, and on the decrement of the oxidative stress on the other hand. Moreover the effect of Niacin on paraoxonase activity could have beneficial effect since PON1 protects HDL as well as LDL from oxidation. Although Niacin did not significantly affected CRP levels in the hypercholesterolemic patients, an inverse linear correlation between CRP serum levels and HDL-C levels was detected, illustrating the higher inflammatory status in low HDL patients as well as an associated reduction in inflammation following Niacin increasing effect on HDL. Our study is the first study that examined the direct effect of niacin administration to humans on the oxidative stress, in vivo. Our results are comparable to the known data in the literature in regard to the effect of niacin on the lipid profile. It is the first study that proves in humans the favorable anti-atherogenic properties of niacin, carried out by the anti-atherogenic effects of higher HDL-c levels. Thus, niacin could be effective in patients with hypercholesterolemia, especially those with low HDL-c, because this is the only effective drug that increases HDL-c on one hand and decreases the oxidative stress on the other hand. This effect would be more dramatic in patients with coronary heart disease or diabetes mellitus, or in patients with multiple risk factors for atherosclerosis.

CONCLUSION Rambam health care campus, Haifa, Israel Niacin treatment to hypercholesterolemic patients with low HDL levels caused a significant decrease in their oxidative stress status. These results indicate an additional beneficial effect of Niacin beyond its ability to affect lipid profile

Thank you !